Research profile Explore published studies, research topics and source-specific findings below.
01 / OVERVIEW
What is it?
Nephropept is a kidney-derived polypeptide mixture in the organ-extract research tradition. It is not a single defined peptide. The linked Phase II listing describes a clinical development plan; it does not provide trial outcomes.
A kidney-derived polypeptide complex explicitly studied in rat tissue cultures and listed in a Phase II development program for chronic kidney disease with type 2 diabetes. It is distinct from oral Pielotax and from synthetic EDL.
Selected study findings
in vitro · 2023
Study of multiple preparations · Indexed abstract; full methods not assessed
Rat spleen, liver, kidney and brain-cortex explant cultures
The report explicitly identifies Nephropept as the kidney complex alongside Thymalin, Ventvil and Cortexin. Corresponding tissue explant growth increased by approximately 20–27%; combining preparations with Thymalin did not add a potentiating effect.
Limit: Explant-area growth is a laboratory endpoint, not evidence of organ regeneration in patients. Combined-extract findings do not support a clinical combination regimen or prove shared composition.
Selected findings, not a systematic review or a treatment recommendation. Combination and related-preparation results cannot be attributed to this compound alone. See each source for access status and remaining limitations.
Compound class
Tissue-derived polypeptide preparation
Research collection
Peptide bioregulation · editorial grouping
Research institutions
No institutional affiliation recorded
Source review
Review dates and the material assessed are listed with each publication below.
02 / EVIDENCE DIMENSIONS
Evidence assessment
Human research
—Phase II protocol listed; numerical clinical results not recovered
Study methods
—Original findings separated from registry records and related-product research
Independent replication
—Independent confirmation not established by these linked records
Source access
—Source-specific review scopes accompany each record
Safety evidence
—Preparation-specific safety data are required; related products cannot substitute
These fields describe different aspects of the evidence. A missing record does not mean that no research exists.
Research context, history and detailed findingsEVIDENCE REVIEW / 6 OCTOBER 2026
Outstanding review questions
Appraise original methods and replication; keep animal and cell findings separate from unestablished human benefit and safety.
No human intervention report has been identified among the linked records; unclassified archival leads may remain. Publication records can share participants. Source counts are not trial counts.
Evidence belongs to the preparation actually studied. A tissue extract and a synthetic peptide can belong to the same research tradition without having equivalent effects or safety.
Kidney: the molecular link
Nephropept / separately formulated Pielotax → AED, EDL and AEDG are related experimental sequences
A common tissue target does not establish identical extracts or prove that these sequences were isolated from Nephropept.
Clinical evidence and limitations
Pielotax has a historical institute report. The Nephropept Phase II registry reproduction lists a planned 210-person CKD study without numerical outcomes.
Recover the original protocol, actual enrollment, clinical-study report and preparation characterization.
N. I. Chalisova, G. A. Ryzhak, E. S. Egorova · Molecular Medicine. 2023;(1).
The report explicitly identifies Nephropept as the kidney complex alongside Thymalin, Ventvil and Cortexin. Corresponding tissue explant growth increased by approximately 20–27%; combining preparations with Thymalin did not add a potentiating effect.
Population / setting
Rat spleen, liver, kidney and brain-cortex explant cultures
What was checked
Publisher English abstract and linked Russian PDF abstract checked.
Limitations & review scope
Explant-area growth is a laboratory endpoint, not evidence of organ regeneration in patients.
Combined-extract findings do not support a clinical combination regimen or prove shared composition.
Source checked 2026-10-07. See the review scope above for the material assessed.
Read the source ↗2023 · Nephropept NPR-11-2022: Phase II trial registration
PeptidPRO (sponsor listed in registry reproduction) · Protocol NPR-11-2022; authorization 340 dated 30 June 2023.
The public registry reproduction describes a multicenter double-blind randomized placebo-controlled Phase II protocol. It lists dates of June 2023 to December 2024 and a target of 210 participants. This record contains no numerical efficacy or safety results.
Population / setting
Planned registry population: 210 patients with stage 3a–3b CKD and type 2 diabetes
What was checked
ClinLine registry reproduction checked; original regulatory record and results not recovered.
Limitations & review scope
Secondary registry reproduction, not the full protocol or a clinical-study report. Dates do not verify completion or actual enrollment.
Formulation and objective fields differ on strength; dose arms are not inferred. No treatment benefit is asserted.
Source checked 2026-10-07. See the review scope above for the material assessed.